180 related articles for article (PubMed ID: 3009551)
21. Hypophosphatemic rickets/osteomalacia in linear sebaceous nevus syndrome: a variant of tumor-induced osteomalacia.
Carey DE; Drezner MK; Hamdan JA; Mange M; Ahmad MS; Mubarak S; Nyhan WL
J Pediatr; 1986 Dec; 109(6):994-1000. PubMed ID: 3023599
[TBL] [Abstract][Full Text] [Related]
22. Impaired stimulation of 25-hydroxyvitamin D-24-hydroxylase in fibroblasts from a patient with vitamin D-dependent rickets, type II. A form of receptor-positive resistance to 1,25-dihydroxyvitamin D3.
Griffin JE; Zerwekh JE
J Clin Invest; 1983 Oct; 72(4):1190-9. PubMed ID: 6313754
[TBL] [Abstract][Full Text] [Related]
23. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse.
Marie PJ; Travers R; Glorieux FH
Endocrinology; 1982 Sep; 111(3):904-11. PubMed ID: 6896684
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D resistance and alopecia: a kindred with normal 1,25-dihydroxyvitamin D binding, but decreased receptor affinity for deoxyribonucleic acid.
Hirst MA; Hochman HI; Feldman D
J Clin Endocrinol Metab; 1985 Mar; 60(3):490-5. PubMed ID: 2982898
[TBL] [Abstract][Full Text] [Related]
25. Effect of the X-linked Hyp mutation and vitamin D status on induction of renal 25-hydroxyvitamin D3-24-hydroxylase.
Tenenhouse HS; Jones G
Endocrinology; 1987 Feb; 120(2):609-16. PubMed ID: 3803293
[TBL] [Abstract][Full Text] [Related]
26. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
27. Bone and serum concentrations of osteocalcin as a function of 1,25-dihydroxyvitamin D3 circulating levels in bone disorders in rats.
Lian JB; Carnes DL; Glimcher MJ
Endocrinology; 1987 May; 120(5):2123-30. PubMed ID: 3494594
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D metabolism is altered in Asian Indians in the southern United States: a clinical research center study.
Awumey EM; Mitra DA; Hollis BW; Kumar R; Bell NH
J Clin Endocrinol Metab; 1998 Jan; 83(1):169-73. PubMed ID: 9435436
[TBL] [Abstract][Full Text] [Related]
29. Hereditary resistance to 1,25-dihydroxyvitamin D.
Marx SJ; Liberman UA; Eil C; Gamblin GT; DeGrange DA; Balsan S
Recent Prog Horm Res; 1984; 40():589-620. PubMed ID: 6091196
[No Abstract] [Full Text] [Related]
30. Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells.
Chen TL; Hauschka PV; Feldman D
Endocrinology; 1986 Mar; 118(3):1119-26. PubMed ID: 3004896
[TBL] [Abstract][Full Text] [Related]
31. Specific internalization and action of 1,25-dihydroxyvitamin D3 in cultured dermal fibroblasts from patients with X-linked hypophosphatemia.
Adams JS; Gacad MA; Singer FR
J Clin Endocrinol Metab; 1984 Sep; 59(3):556-60. PubMed ID: 6547728
[TBL] [Abstract][Full Text] [Related]
32. Response of rachitic rat bones to 1,25-dihydroxyvitamin D3: biphasic effects on mineralization and lack of effect on bone resorption.
Gallagher JA; Beneton M; Harvey L; Lawson DE
Endocrinology; 1986 Oct; 119(4):1603-9. PubMed ID: 3757903
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D-dependent rickets types I and II. Diagnosis and response to therapy.
Silver J; Landau H; Bab I; Shvil Y; Friedlaender MM; Rubinger D; Popovtzer MM
Isr J Med Sci; 1985 Jan; 21(1):53-6. PubMed ID: 2982764
[TBL] [Abstract][Full Text] [Related]
34. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
Ecarot B; Glorieux FH; Desbarats M; Travers R; Labelle L
J Bone Miner Res; 1995 Mar; 10(3):424-31. PubMed ID: 7785464
[TBL] [Abstract][Full Text] [Related]
35. 25-Hydroxyvitamin D-24-hydroxylase in phytohemagglutinin-stimulated lymphocytes: intermediate bioresponse to 1,25-dihydroxyvitamin D3 of cells from parents of patients with vitamin D-dependent rickets type II.
Takeda E; Yokota I; Ito M; Kobashi H; Saijo T; Kuroda Y
J Clin Endocrinol Metab; 1990 Apr; 70(4):1068-74. PubMed ID: 2156884
[TBL] [Abstract][Full Text] [Related]
36. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF; Breed AL
Pediatrics; 1983 Apr; 71(4):559-67. PubMed ID: 6300745
[TBL] [Abstract][Full Text] [Related]
37. Prenatal diagnosis of vitamin D-dependent rickets, type II: response to 1,25-dihydroxyvitamin D in amniotic fluid cells and fetal tissues.
Weisman Y; Jaccard N; Legum C; Spirer Z; Yedwab G; Even L; Edelstein S; Kaye AM; Hochberg Z
J Clin Endocrinol Metab; 1990 Oct; 71(4):937-43. PubMed ID: 2169482
[TBL] [Abstract][Full Text] [Related]
38. Calcitriol treatment in vitamin D-dependent and vitamin D-resistant rickets.
Glorieux FH
Metabolism; 1990 Apr; 39(4 Suppl 1):10-2. PubMed ID: 2157942
[TBL] [Abstract][Full Text] [Related]
39. Abnormal 24-hydroxylation of 25-hydroxyvitamin D in the X-linked hypophosphatemic mouse.
Cunningham J; Gomes H; Seino Y; Chase LR
Endocrinology; 1983 Feb; 112(2):633-8. PubMed ID: 6600222
[TBL] [Abstract][Full Text] [Related]
40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
